AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-09-28 View volume: 9
Single B cell cloning isolates individual antigen-specific B cells and recovers their antibody genes directly, without hybridoma immortalization or display library construction. This approach preserves natural heavy–light chain pairing and accesses the full diversity of the in vivo immune response. This guide explains the technology workflow, sorting strategies, and how single B cell cloning compares to other antibody discovery methods.
The workflow consists of four core steps. First, B cells are harvested from immunized animals or human donors — typically from spleen, lymph nodes, bone marrow (for plasma cells), or peripheral blood (for memory B cells and plasmablasts). Second, antigen-specific B cells are identified and sorted at single-cell resolution, most commonly by fluorescence-activated cell sorting (FACS) using fluorescently labeled antigen as the selection probe. Third, VH and VL genes are recovered from individual sorted cells by single-cell RT-PCR and nested PCR amplification. Fourth, the recovered antibody genes are cloned into expression vectors and transiently expressed for functional screening. The entire process from sorted cell to recombinant antibody in hand takes approximately 3–4 weeks.
| Cell Type | Source | Surface Markers | Characteristics |
|---|---|---|---|
| Memory B cells | Spleen, lymph nodes, PBMCs | IgG+, CD27+ (human); IgG+, IgD−, IgM− (mouse) | Affinity-matured, class-switched; express surface BCR for antigen-based FACS sorting |
| Plasmablasts | PBMCs (day 7–10 post-boost) | CD19+, CD27hi, CD38hi (human) | Transiently abundant after vaccination/boost; high antibody secretion rate; lower surface BCR |
| Plasma cells (long-lived) | Bone marrow | CD138+, CD38hi | Highest affinity-matured antibodies; minimal surface BCR — require secretion-based sorting |
| Germinal center B cells | Spleen, lymph nodes (mid-response) | GL7+, Fas+ (mouse) | Actively undergoing somatic hypermutation; captures diversity before selection narrows the repertoire |
FACS with labeled antigen: The most common approach. Antigen is labeled with two different fluorophores (e.g., AF647 and PE); double-positive B cells are sorted, and single-fluorophore-positive cells are excluded to eliminate fluorophore binders. This dual-color strategy dramatically reduces false positives.
Antigen-negative deselection: For membrane targets, cells can be pre-incubated with antigen-negative parental cells to deplete B cells reactive to shared surface antigens, enriching for target-specific clones before FACS.
Microfluidic droplet sorting: Encapsulates individual B cells in nanoliter droplets with antigen-coated beads and a fluorogenic detection reagent. Secreted antibody that binds the bead triggers a fluorescent signal, enabling sorting of antibody-secreting cells (plasmablasts, plasma cells) that lack sufficient surface BCR for conventional FACS.
Nanowell-based screening: Single cells are arrayed in microwells and screened for antigen binding by fluorescence microscopy or microengraving. Enables simultaneous functional characterization (binding, blocking, cross-reactivity) before gene recovery.
| Feature | Hybridoma | Single B Cell Cloning | Phage Display |
|---|---|---|---|
| HC–LC pairing | Preserved (one cell = one antibody) | Preserved (native pairing recovered by single-cell RT-PCR) | Lost (random VH–VL recombination during library construction) |
| Repertoire sampling | Limited by fusion efficiency (~1 in 105 B cells forms a viable hybridoma) | Broad — any B cell that binds labeled antigen can be sorted | Library diversity (109–1011), but biased by display and expression efficiency |
| Timeline | 3–6 months (including immunization) | 6–10 weeks (post-immunization to recombinant antibody) | 4–8 weeks (from library to hits; longer with immunized library construction) |
| Species flexibility | Mouse (myeloma partners available); rabbit, rat (specialized) | Any species including human, llama/alpaca, chicken | Species-independent (library-based) |
| Sequence access | Requires separate sequencing step after screening | Sequence known immediately (recovered by PCR) | Sequence known immediately (from phagemid) |
The main challenge is PCR recovery rate. Not every sorted B cell yields amplifiable VH and VL sequences — typical recovery rates range from 30% to 70% depending on cell type, sort purity, and PCR primer coverage. Plasma cells and plasmablasts have higher mRNA content per cell but lower surface BCR for sorting. Memory B cells sort cleanly by antigen binding but contain less antibody mRNA. Optimization of primer sets covering all V-gene families and careful handling of single-cell lysates (avoiding mRNA degradation) are essential for maximizing recovery. Multiplexing with oligo-dT and gene-specific primers, combined with nested PCR, achieves the best results.
A second consideration is throughput versus depth. FACS can sort hundreds to thousands of antigen-positive cells per session, but each cell requires individual RT-PCR, cloning, and expression — a labor-intensive process. High-throughput single-cell sequencing platforms (10x Genomics, CITE-seq) now enable paired VH–VL sequencing of thousands of B cells simultaneously, dramatically increasing repertoire sampling depth. However, functional validation still requires recombinant expression of selected candidates.
• Human antibody discovery from patient samples: Recovering naturally paired human antibodies from convalescent or vaccinated donors without the need for humanization.
• Non-mouse host species: When rabbit, alpaca, or chicken antibodies are needed and species-specific hybridoma partners are unavailable or unreliable.
• Rare specificities: When the target elicits a weak immune response and every antigen-specific B cell counts — hybridoma fusion efficiency would discard most of these rare clones.
• Preserving natural VH–VL pairing: When combinatorial pairing in phage display would scramble the heavy–light chain pairs that evolved together in vivo, potentially losing optimal binding geometries.
• Speed: When recombinant antibody sequences are needed in weeks rather than months, and immediate sequence access enables rapid downstream validation.
Interested in single B cell antibody discovery? AtaGenix offers single B cell cloning from multiple species alongside hybridoma and phage display platforms for comprehensive antibody discovery campaigns.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-65523339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
